热门资讯> 正文
在OLC因高磷血症获得第二次RTL后，单胞菌销量暴跌
2026-07-01 02:05
- Unicycive Therapeutics is down ~37% in Tuesday afternoon trading after announcing it has received a Complete Response Letter from the FDA for its resubmitted NDA for oxylanthanum carbonate (OLC) to treat hyperphosphatemia in patients with chronic kidney disease on dialysis.
- The company had received another CRL in June 2025 related to manufacturing issues at a third-party site.
- The problem this time is that the agency was unable to reinspect the site by the action date, which was June 26.
- No additional data has been requested by the FDA.
- In a recent interview with Seeking Alpha, Unicycive CEO Shalabh Gupta explained how OLC would compete in a crowded hyperphosphatemia market.
More on Unicycive Therapeutics
- Unicycive Therapeutics: A Catalyst Play With Real Fundamental Upside
- Unicycive Therapeutics, Inc. (UNCY) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
- Unicycive seeks to distinguish OLC in crowded CKD hyperphosphatemia market
- Biopharmas look to China, elsewhere for partnerships, R&D
- Seeking Alpha’s Quant Rating on Unicycive Therapeutics
推荐文章
美股前瞻 | 全球第三大IPO！海力士获大幅超额认购；双重催化！SpaceX期权多头狂热押注大涨；大摩喊话：资金将轮动至超大规模云厂商
华盛早报 | 存储爆利好！传三星第三季DRAM拟提价20%；美伊下一轮谈判将于11日在巴基斯坦进行
科技股震荡之际，投资者密切关注美联储的动向及企业财报信号
港股周报 | 市场风格切换！存储、光通信股暴跌，科指反弹近6%；花旗称科网股估值极具吸引力；创新药、机器人概念飙涨
一周IPO | 史上最大ADR来袭！SK海力士或下周五登陆美股；16只新股即将上市！“今年最贵新股”鼎泰高科火热招股中
年中盘点 | 存储概念“强者恒强”！闪迪年内狂飙858%霸榜美股升幅Top10，康宁势将成为下半年最大黑马？
一周财经日历 | 美联储会议纪要重磅来袭；SK海力士拟7月10日登陆美股；智谱、MiniMax限售股将解禁
华盛早报 | 美股冰火两重天！道指狂飙近600点，存储却遭恐慌性抛售；“大空头”Burry唱空美股半导体面临30%回调
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
